Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Dementia l: Introduction

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Extracting and Classifying Drug Discontinuations From Estonian Electronic Health Records: Development and Validation Study.

Journal of medical Internet research·2026

Same author

Caregiver-Associated Physical Activity Patterns, Dietary Behaviors and Interventional Beliefs in Individuals with Down Syndrome: Insights from a Large European Survey.

Nutrients·2026

Same author

Understanding Obesity in Individuals with Down Syndrome: Caregiver Perceptions, Awareness, and Motivation.

Nutrients·2026

Same author

Impaired vitamin D signaling reveals novel targets in tooth and alveolar bone.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Same author

Assessing the de novo paradigm in sporadic early-onset Alzheimer disease trios.

Molecular psychiatry·2026

Same author

Age-related behavioral and molecular landmarks in new mouse models for studying Alzheimer's disease in Down syndrome.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

HENA, heterogeneous network-based data set for Alzheimer's disease.

Elena Sügis^1,2, Jerome Dauvillier³, Anna Leontjeva⁴

¹Quretec Ltd., Ülikooli 6a, 51003, Tartu, Estonia.

Scientific Data

|August 16, 2019

Summary

This study introduces HENA, a novel data set for Alzheimer's disease research. HENA integrates diverse experimental data, enabling a comprehensive analysis of dementia mechanisms and potential drug targets.

More Related Videos

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Published on: May 20, 2024

Related Experiment Videos

Last Updated: Jun 27, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data

Published on: December 15, 2023

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Published on: May 20, 2024

Area of Science:

Neuroscience
Bioinformatics
Genomics

Background:

Alzheimer's disease (AD) and other dementias are leading causes of disability in older adults.
Understanding AD's complex mechanisms requires integrating data from diverse scientific fields.
Current data storage in separate databases hinders a holistic disease view.

Purpose of the Study:

To introduce HENA (Heterogeneous network-based data set for Alzheimer's disease).
To demonstrate the utility of graph convolutional networks (deep learning) for analyzing complex biological data.
To provide a platform for scientists to contextualize their AD research findings.

Main Methods:

Development of a heterogeneous network-based data set (HENA) for Alzheimer's disease.
Application of graph convolutional networks (GCNs), a deep learning approach.
Integration of data from proteomics, molecular biology, clinical diagnostics, and genomics.

Main Results:

HENA successfully integrates diverse, complementary datasets for Alzheimer's disease research.
Graph convolutional networks effectively analyze large, heterogeneous biological datasets.
The study demonstrates a novel approach to systematically view AD data.

Conclusions:

HENA offers a unified resource for Alzheimer's disease research.
Deep learning methods, like GCNs, are powerful tools for analyzing integrated biological data.
This approach facilitates a broader understanding of AD mechanisms and potential therapeutic targets.